ENDRA Life Sciences (NDRA) EBITDA Margin (2016 - 2018)

ENDRA Life Sciences (NDRA) has reported EBITDA Margin for 3 consecutive years, with 45960.77% the latest figure, recorded in Q1 2018.

• On a quarterly basis, EBITDA Margin changed N/A year-over-year to 45960.77% in Q1 2018; TTM through Dec 2018 was 146080.47%, a 14476512.0% decrease from a year earlier, with the FY2018 full-year figure at 146080.47%, down 14476483.0% from the prior year.
• EBITDA Margin was 45960.77% for Q1 2018 at ENDRA Life Sciences, down from 33526.58% in the prior quarter.
• Over five years, EBITDA Margin peaked at 61.85% in Q4 2016 and troughed at 45960.77% in Q1 2018.
• A 3-year average of 16339.19% and a median of 1829.36% in 2017 frame the typical range for EBITDA Margin.
• The widest YoY moves for EBITDA Margin: up 3346474 bps in 2017, down 3346474 bps in 2017.
• Over 3 years, EBITDA Margin stood at 61.85% in 2016, then tumbled by 54107 bps to 33526.58% in 2017, then sank by 37 bps to 45960.77% in 2018.
• The last three EBITDA Margin figures came in at 45960.77% (Q1 2018), 33526.58% (Q4 2017), and 317.4% (Q3 2017), per Business Quant data.